XORTX Therapeutics (XRTX) Change in Accured Expenses (2020 - 2026)

XORTX Therapeutics (XRTX) has 7 years of Change in Accured Expenses data on file, last reported at -$33529.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 1813.76% year-over-year to -$33529.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $131026.0 (down 78.47% YoY) and the FY2025 annual result came in at $162803.0, down 21.79% from the prior year.
• Change in Accured Expenses slipped to -$33529.0 in Q1 2026, from $7835.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $438831.5 in Q2 2022 to a low of -$402068.0 in Q1 2024.
• A 5-year average of $64439.5 and a median of $78658.0 in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 1367.11% — and 2026, when it sank 1813.76%.
• Tracing XRTX's Change in Accured Expenses over 5 years: stood at -$306384.4 in 2022, then soared by 51.68% to -$148039.0 in 2023, then surged by 145.76% to $67736.0 in 2024, then sank by 88.43% to $7835.0 in 2025, then sank by 527.94% to -$33529.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$33529.0 (Q1 2026), $7835.0 (Q4 2025), and $67145.0 (Q3 2025), per Business Quant data.